Related Experiment Video
Updated: Mar 18, 2026
Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
Published on: September 27, 2024
Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and
Sarah H Hsu1, Stephanie D Gan, Bichchau T Nguyen
1*Department of Dermatology, Boston Medical Center, Boston University, Boston, Massachusetts; †Department of Dermatology, University of Michigan, Ann Arbor, Michigan; ‡Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts; §Division of Dermatology, Veterans Affairs-Boston Hospitals, Boston Medical Center, Boston University, Boston, Massachusetts; ‖ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Background:
The authors previously reported the safety and short-term efficacy of ablative fractional laser (AFXL)-assisted delivery of topical fluorouracil in the treatment of superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis).
Objective:
This follow-up study was conducted to assess whether tumor clearance was sustained in this cohort of patients at >9 months post-treatment.
Methods:
Thirty primary sBCC or SCCis <2 cm on the trunk or extremities were treated with AFXL and a single application of topical 5-fluorouracil 5% under occlusion for 7 days. Among the 26 patients who achieved tumor clearance at 4 to 8 weeks post-treatment, 20 patients presented for this follow-up study and underwent shave biopsy to confirm histologic clearance. Mean follow-up time was 15 months.
Results:
Considering those who had persistent tumor at 4 to 8 weeks post-treatment and those who presented for follow-up at >9 months post-treatment, overall treatment success was 79% (95% confidence interval: 67%-96%), with 92% (11/12) for SCCis and 67% (8/12) for sBCC. Neither the tumor location nor size significantly impacted treatment outcome (p = .96 and 0.87, respectively).
Conclusion:
Ablative fractional laser-assisted topical fluorouracil is a reasonable noninvasive treatment option for primary SCCis and sBCC, especially for lesions located in areas where self-application is not possible, or when clinician-administered therapy is preferred.
